Congresos 2023
En esta página podrá descargarse la información más relevante de Larotrectinib presentada en los congresos de 2023.
- Larotrectinib in Adultsexpand_more
Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer. (Hong DS, et al. J Clin Oncol 41, 2023 (suppl 16; abstr 3141).
- Larotrectinib in TRK fusion Lung Cancerexpand_more
Long-term efficacy and safety of Larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer. (Lin JJ, et al. J Clin Oncol 41, 2023 (suppl 16; abstr 9056).
- Larotrectinib in TRK fusion Thyroid Carcinomaexpand_more
Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC). (Cabanillas ME, et al. J Clin Oncol 41, 2023 (suppl 16; abstr 6091).
- Larotrectinib Extended Data Setexpand_more
Larotrectinib Extended Data Set (A. Drilon, et al, Annals of Oncology, Volume 34, Suplement 2, 2023, Page S470.
- Larotrectinib as first-line treatmentexpand_more
Efficacy and safety of Larotrectinib as first-line treatment for patients with TRK fusion cancer (Hong DS, et al, Annals of Oncology, Volume 34, Suplement 2, 2023, Page S469).
- Larotrectinib in TRK fusion sarcomasexpand_more
Updated efficacy and safety of Larotrectinib in adult patients with TRK fusion sarcomas (McDermott R, et al. Poster presentation at CTOS 2023:Abstract 1569432).
- Efficacy, safety, and treatment hold wait-and-see outcomes of Larotrectinib in pediatric patientsexpand_more
Efficacy, safety, and treatment hold wait-and-see outcomes of Larotrectinib in pediatric patients with TRK fusion sarcomas (Albert CM, et al. Poster presentation at CTOS 2023:Abstract 1570241).
- Larotrectinib Historical Comparison Orbachexpand_more
Comparison of clinical outcomes of patients with infantile fibrosarcoma treated with Larotrectinib in the SCOUT study versus historical cohort THE EPI-VITRAKVI STUDY (D. Orbach, et al.44O. ESMO Open, Volume 8, Issue 1, Supplement 3, 2023).
- Larotrectinib Dataexpand_more
Efficacy and safety of Larotrectinib in patients with TRK fusion primary central nervous system tumors: An updated analysis (Perreault S, et al. Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v95).